Dianthus Therapeutics Inc. Cash Flow-to-Debt Ratio
Dianthus Therapeutics Inc. cash flow-to-debt ratio. Dianthus Therapeutics Inc. (DNTH) has a Cash Flow-to-Debt Ratio of -1.19x as of June 2026, meaning its operating cash flow of $-48.98 Million could theoretically repay -1% of its total liabilities ($41.25 Million) in one year. See DNTH financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Dianthus Therapeutics Inc. (2016–2025)
Cash flow-to-debt ratio of Dianthus Therapeutics Inc. from 2016 to 2025. Historical debt coverage capacity for Dianthus Therapeutics Inc. across 10 annual periods. Check Dianthus Therapeutics Inc. (DNTH) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Dianthus Therapeutics Inc. Cash Flow-to-Debt Ratio by Year (2016–2025)
Dianthus Therapeutics Inc. cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Dianthus Therapeutics Inc.. For the full cash flow conversion analysis, see DNTH cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.44x | $-129.06 Million | $37.52 Million | ▲ +5.3% |
| 2024 | -3.63x | $-78.18 Million | $21.53 Million | ▼ -3.8% |
| 2023 | -3.50x | $-36.86 Million | $10.54 Million | ▼ -13.8% |
| 2022 | -3.07x | $-29.07 Million | $9.45 Million | ▲ +10.8% |
| 2021 | -3.45x | $-59.53 Million | $17.26 Million | ▲ +4.6% |
| 2020 | -3.61x | $-64.02 Million | $17.71 Million | ▼ -28.6% |
| 2019 | -2.81x | $-57.10 Million | $20.32 Million | ▲ +21.7% |
| 2018 | -3.59x | $-41.89 Million | $11.66 Million | ▲ +33.2% |
| 2017 | -5.37x | $-22.26 Million | $4.14 Million | ▼ -89.3% |
| 2016 | -2.84x | $-6.53 Million | $2.30 Million | — |